ESR1 and breast cancer: Experiments were conducted using established human breast cancer cells lines rather than cells from patient-derived xenografts (PDX) models; while PDX models recapitulate aspects of patient-specific responses across a range of human tumors, ER+ PDXs are reported to have a much lower take rate and tend not to metastasize to bone [67,68,69].